Notice of Termination of Sales Agreement between Qualigen Therapeutics, Inc. and A.G.P./Alliance Global Partners
Qualigen Therapeutics, Inc. (formerly Ritter Pharmaceuticals, Inc.) is notifying A.G.P./Alliance Global Partners of its decision to terminate their Sales Agreement dated November 6, 2019. The termination will be effective July 3, 2021, unless both parties agree to an earlier date. This letter serves as the formal notice required under the agreement, and requests confirmation if the termination can be accelerated to June 25, 2021.
Exhibit 10.2
June 22, 2021
VIA FEDEX
A.G.P./Alliance Global Partners
590 Madison Avenue
New York, NY 10022
Attention: Tom Higgins
Re: Termination of Sales Agreement with Ritter Pharmaceuticals, Inc. (nka Qualigen Therapeutics, Inc.)
Gentlemen,
Pursuant to Section 11(b) of the Sales Agreement dated November 6, 2019 between you and Ritter Pharmaceuticals, Inc. (now known as Qualigen Therapeutics, Inc.), we hereby notify you that we are terminating such Sales Agreement. Allowing for the required advance-notice period, the effective date of the termination will be July 3, 2021. It would be convenient and much appreciated if we could agree that the date of termination could be accelerated to June 25; please email if this is acceptable.
| Very truly yours, | |
| /s/ Michael S. Poirier | |
| Michael S. Poirier | |
| Chairman, Chief Executive Officer and President, | |
| Qualigen Therapeutics, Inc. |
| cc (via FedEx): | Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| 666 Third Avenue | |
| New York, New York 10017 | |
| Attention: Anthony J. Marsico, Esq. |
